Neutral sphingomyelinase 2 modulates cytotoxic effects of protopanaxadiol on different human cancer cells

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Park, Bonggoo ^a,f   Lee, Yong Moon ^c   Kim, Jae Sung ^d   Her, Youl ^e   Kang, Ju Hee ^b   Oh, Seung Hyun ^a   Kim, Hwan Mook ^a  

^a Gachon University College of Medicine   (South Korea)

^b National Cancer Center   (South Korea)

^c Chungbuk National University   (South Korea)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e BTGin Co Ltd   (South Korea)

^f Korea University College of Medicine   (South Korea)

Author keywords

Ceramide; Chemosensitization; Lipid raft; Neutral sphingomyelinase; Protopanaxadiol

Indexed keywords

ANTINEOPLASTIC AGENT; CERAMIDE DERIVATIVE; CHOLESTEROL; CISPLATIN; DOXORUBICIN; METHYL BETA CYCLODEXTRIN; PROTOPANAXADIOL; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE; SPHINGOMYELIN PHOSPHODIESTERASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GINSENG; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; LEUKEMIA CELL; LIPID RAFT; LUNG CANCER; MEMBRANE DAMAGE; MOUSE; NONHUMAN; PROSTATE CANCER; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WEIGHT REDUCTION;

ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CYTOTOXINS; FEMALE; GINSENOSIDES; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; PANAX; SAPOGENINS; SPHINGOMYELIN PHOSPHODIESTERASE;

EID: 84880940448     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-194     Document Type: Article

References (33)

1. Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin Med 2010, 5:20. 10.1186/1749-8546-5-20, 2893180, 20537195.
2. Nag SA, Qin JJ, Wang W, Wang MH, Wang H, Zhang R. Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. Front Pharmacol 2012, 3:25. 3289390, 22403544.
3. Wang W, Zhao Y, Rayburn ER, Hill DL, Wang H, Zhang R. In vitro anti-cancer activity and structure-activity relationships of natural products isolated from fruits of Panax ginseng. Cancer Chemother Pharmacol 2007, 59:589-601. 10.1007/s00280-006-0300-z, 16924497.
4. Babina IS, Donatello S, Nabi IR, Hopkins AM. Lipid Rafts as Master Regulators of Breast Cancer Cell Function. Breast cancer - carcinogenesis, cell growth and signalling pathways 2011, 401-428. New York: INTECH, Gunduz M, Gunduz E.
5. George KS, Wu S. Lipid raft: a floating island of death or survival. Toxicol Appl Pharmacol 2012, 259:311-319. 10.1016/j.taap.2012.01.007, 3299927, 22289360.
6. Kabouridis PS, Janzen J, Magee AL, Ley SC. Cholesterol depletion disrupts lipid rafts and modulates the activity of multiple signaling pathways in T lymphocytes. Eur J Immunol 2000, 30:954-963. 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.0.CO;2-Y, 10741414.
7. Yi JS, Choo HJ, Cho BR, Kim HM, Kim YN, Ham YM, Ko YG. Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem Biophys Res Commun 2009, 385:154-159. 10.1016/j.bbrc.2009.05.028, 19445898.
8. Park EK, Lee EJ, Lee SH, Koo KH, Sung JY, Hwang EH, Park JH, Kim CW, Jeong KC, Park BK, Kim YN. Induction of apoptosis by the ginsenoside Rh2 by internalization of lipid rafts and caveolae and inactivation of Akt. Br J Pharmacol 2010, 160:1212-1223. 10.1111/j.1476-5381.2010.00768.x, 2936029, 20590613.
9. Wang W, Rayburn ER, Hao M, Zhao Y, Hill DL, Zhang R, Wang H. Experimental therapy of prostate cancer with novel natural product anti-cancer ginsenosides. Prostate 2008, 68:809-819. 10.1002/pros.20742, 18324646.
10. Wang W, Rayburn ER, Hang J, Zhao Y, Wang H, Zhang R. Anti-lung cancer effects of novel ginsenoside 25-OCH(3)-PPD. Lung Cancer 2009, 65:306-311. 10.1016/j.lungcan.2008.11.016, 2748063, 19131140.
11. Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer 2008, 98:792-802. 10.1038/sj.bjc.6604227, 2259179, 18253123.
12. Liu Y, Yang G, Bu X, Liu G, Ding J, Li P, Jia W. Cell-type-specific regulation of raft-associated Akt signaling. Cell Death Dis 2011, 2:e145. 10.1038/cddis.2011.28, 3122059, 21490677.
13. Andrieu-Abadie N, Jaffrezou JP, Hatem S, Laurent G, Levade T, Mercadier JJ. L-carnitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation. FASEB J 1999, 13:1501-1510.
14. Kim HM, Han SB, Kim MS, Kang JS, Oh GT, Hong DH. Efficient fixation procedure of human leukemia cells in sulforhodamine B cytotoxicity assay. J Pharmacol Toxicol Methods 1996, 36:163-169. 10.1016/S1056-8719(96)00113-X, 8959582.
15. Bielawski J, Szulc ZM, Hannun YA, Bielawska A. Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 2006, 39:82-91. 10.1016/j.ymeth.2006.05.004, 16828308.
16. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
17. Jost LM, Kirkwood JM, Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J Immunol Methods 1992, 147:153-165. 10.1016/S0022-1759(12)80003-2, 1548398.
18. Kim WH, Choi CH, Kang SK, Kwon CH, Kim YK. Ceramide induces non-apoptotic cell death in human glioma cells. Neurochem Res 2005, 30:969-979. 10.1007/s11064-005-6223-y, 16258846.
19. Mondal S, Mandal C, Sangwan R, Chandra S. Withanolide D induces apoptosis in leukemia by targeting the activation of neutral sphingomyelinase-ceramide cascade mediated by synergistic activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinase. Mol Cancer 2010, 9:239. 2949798, 20836852.
20. Luberto C, Hassler DF, Signorelli P, Okamoto Y, Sawai H, Boros E, Hazen-Martin DJ, Obeid LM, Hannun YA, Smith GK. Inhibition of tumor necrosis factor-induced cell death in MCF7 by a novel inhibitor of neutral sphingomyelinase. J Biol Chem 2002, 277:41128-41139. 10.1074/jbc.M206747200, 12154098.
21. Ji C, Yang B, Yang YL, He SH, Miao DS, He L, Bi ZG. Exogenous cell-permeable C6 ceramide sensitizes multiple cancer cell lines to Doxorubicin-induced apoptosis by promoting AMPK activation and mTORC1 inhibition. Oncogene 2010, 29:6557-6568. 10.1038/onc.2010.379, 20802518.
22. Kang JH, Song KH, Woo JK, Park MH, Rhee MH, Choi C, Oh SH. Ginsenoside Rp1 from Panax ginseng exhibits anti-cancer activity by down-regulation of the IGF-1R/Akt pathway in breast cancer cells. Plant Foods Hum Nutr 2011, 66:298-305. 10.1007/s11130-011-0242-4, 21748437.
23. Hong S, Huo H, Xu J, Liao K. Insulin-like growth factor-1 receptor signaling in 3T3-L1 adipocyte differentiation requires lipid rafts but not caveolae. Cell Death Differ 2004, 11:714-723. 10.1038/sj.cdd.4401405, 15002041.
24. Oh SH, Jin Q, Kim ES, Khuri FR, Lee HY. Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression. Clin Cancer Res 2008, 14:1581-1589. 10.1158/1078-0432.CCR-07-0952, 18316583.
25. Werner H. Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 2012, 31:2703-2714. 10.1038/onc.2011.447, 21963847.
26. Gao QG, Chen WF, Xie JX, Wong MS. Ginsenoside Rg1 protects against 6-OHDA-induced neurotoxicity in neuroblastoma SK-N-SH cells via IGF-I receptor and estrogen receptor pathways. J Neurochem 2009, 109:1338-1347. 10.1111/j.1471-4159.2009.06051.x, 19476546.
27. Li Q, Li Y, Wang X, Fang X, He K, Guo X, Zhan Z, Sun C, Jin YH. Co-treatment with ginsenoside Rh2 and betulinic acid synergistically induces apoptosis in human cancer cells in association with enhanced capsase-8 activation, bax translocation, and cytochrome c release. Mol Carcinog 2011, 50:760-769. 10.1002/mc.20673, 21751259.
28. Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004, 206:169-180. 10.1016/j.canlet.2003.08.034, 15013522.
29. Marchesini N, Luberto C, Hannun YA. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J Biol Chem 2003, 278:13775-13783. 10.1074/jbc.M212262200, 12566438.
30. Lacour S, Hammann A, Grazide S, Lagadic-Gossmann D, Athias A, Sergent O, Laurent G, Gambert P, Solary E, Dimanche-Boitrel MT. Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004, 64:3593-3598. 10.1158/0008-5472.CAN-03-2787, 15150117.
31. Kurinna SM, Tsao CC, Nica AF, Jiffar T, Ruvolo PP. Ceramide promotes apoptosis in lung cancer-derived A549 cells by a mechanism involving c-Jun NH2-terminal kinase. Cancer Res 2004, 64:7852-7856. 10.1158/0008-5472.CAN-04-1552, 15520191.
32. Grammatikos G, Teichgraber V, Carpinteiro A, Trarbach T, Weller M, Hengge UR, Gulbins E. Overexpression of acid sphingomyelinase sensitizes glioma cells to chemotherapy. Antioxid Redox Signal 2007, 9:1449-1456. 10.1089/ars.2007.1673, 17576160.
33. Cohen SM, Mukerji R, Cai S, Damjanov I, Forrest ML, Cohen MS. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg 2011, 202:646-652. 10.1016/j.amjsurg.2011.06.027, 21982998.